We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
ALGN Q4 Earnings Top Estimates, Revenues Miss, Stock Falls
Read MoreHide Full Article
Align Technology, Inc. (ALGN - Free Report) delivered fourth-quarter 2024 adjusted earnings per share (EPS) of $2.44, up 0.8% from the year-ago level. The reported figure topped the Zacks Consensus Estimate by 0.4%.
GAAP EPS for the quarter was $1.39, reflecting a decline of 15.2% from $1.64 in the comparable period of 2023.
Full-year adjusted EPS was $9.33, reflecting an 8.4% increase from the 2023 level. The figure surpassed the Zacks Consensus Estimate by 0.1%.
Following the earnings announcement, ALGN stock plunged 0.8% yesterday.
ALGN’s Q4 Revenues
The top line increased 4% year over year to $995.2 million but missed the Zacks Consensus Estimate by 0.2%. Revenues were favorably impacted by foreign exchange of approximately $0.9 million.
Full-year revenues totaled $4.00 billion, up 3.5% from the 2023 level. The figure was in line with the Zacks Consensus Estimate.
ALGN’s Segments in Detail
The company has two reportable segments — Clear Aligner, and Imaging Systems and CAD/CAM Services (Systems and Services).
Revenues in the Clear Aligner segment rose 1.6% year over year to $794.3 million.
Clear Aligner revenues had a 0.1% unfavorable foreign exchange impact.
Revenues from Imaging Systems & CAD/CAM Services rose 14.9% to $200.9 million in the reported quarter. The segment, too, witnessed an unfavorable currency impact of 0.1% year over year.
Margins
Gross profit in the quarter was $696.9 million, up 4.1% year over year. The gross margin expanded 5 basis points (bps) year over year to 70% despite an increase of 3.9% in the cost of net revenues.
SG&A expenses increased 5.6% to $425 million, while R&D expenses rose 15.5% to $94.9 million.
Operating income totaled $177.1 million, down 4.2% year over year. The operating margin contracted 153 bps to 17.8%.
Financial Details of ALGN
The company exited the fourth quarter with cash and cash equivalents of $1.04 billion, compared with $937.4 million at the end of the fourth quarter of 2023.
The cumulative net cash provided by operating activities at the end of 2024 was $738.2 million compared with $785.8 million at the end of 2023.
Stock Repurchase
Currently, $225 million is available for repurchases under ALGN’s $1.0 billion Stock Repurchase Program, authorized in January 2023.
ALGN's Guidance
Align Technology provided its financial outlook for full-year 2025. It also provided a guidance for the first quarter of 2025.
Align Technology, Inc. Price, Consensus and EPS Surprise
For the full year, ALGN expects revenue growth to be in the low single digits, which suggests approximately 2% of unfavorable foreign exchange impact at current spot rates. The Zacks Consensus Estimate for 2025 revenues is pegged at $4.19 billion, suggesting 4.8% growth year over year.
The 2025 GAAP operating margin for the full year is anticipated to be approximately 2 basis points above the 2024 level. The 2025 non-GAAP operating margin is expected to be approximately 22.5%.
To support continued expansion, the company expects to invest in the range of $100-$150 million in capital expenditures, primarily related to building construction and improvements and manufacturing capacity.
For the first quarter, ALGN anticipates worldwide revenues to be in the band of $965-$985 million. The Zacks Consensus Estimate is pegged at $1.02 billion.
Our Take
Align Technology exited the fourth quarter on a mixed note. While earnings beat the Zacks Consensus Estimate, revenues lagged the same. Revenues improved on a year-over-year basis, driven by growth in Clear Aligner volumes and Imaging Systems and CAD/CAM Services revenues.
Clear Aligner's volume growth was driven by increased shipments across all regions the company operates in. It experienced continued growth momentum from sales of iTero Lumina scanners and increased Invisalign Clear Aligner volumes in the EMEA region.
Additionally, ALGN’s Imaging Systems & CAD/CAM Services business segment reported strong growth on a year-over-year basis, primarily due to higher ASPs, improved services revenues and increased non-system revenues driven by upgrades in the leasing rental programs.
During the quarter, Align Technology achieved several cumulative milestones, including 271.6 thousand active Invisalign-trained practitioners, 19.5 million Invisalign patients (including over 5.6 million teens and kids) and more than 2 billion clear aligners manufactured worldwide.
Further, a declining operating income and a contraction of the operating margin are matters of concern.
ALGN’s Zacks Rank and Key Picks
Align Technology currently carries a Zacks Rank #4 (Sell).
Some better-ranked stocks from the broader medical space are Quest Diagnostics (DGX - Free Report) , ResMed (RMD - Free Report) and Cardinal Health (CAH - Free Report) .
Quest Diagnostics reported fourth-quarter 2024 adjusted EPS of $2.23, which topped the Zacks Consensus Estimate by 1.8%. Revenues of $2.62 billion beat the Zacks Consensus Estimate by 1.9%.
DGX has an earnings yield of 5.9% compared with the industry’s 4.1%. The company beat on earnings in each of the trailing four quarters, the average surprise being 3.8%.
ResMed, carrying a Zacks Rank #2 at present, posted second-quarter fiscal 2025 adjusted EPS of $2.43, which topped the Zacks Consensus Estimate by 5.6%. Revenues of $1.28 billion exceeded the Zacks Consensus Estimate by 1.6%.
RMD has an estimated fiscal 2025 earnings growth rate of 21.9% compared with the industry’s 13.2%. The company’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 6.9%.
Cardinal Health, carrying a Zacks Rank #2 at present, posted second-quarter fiscal 2025 adjusted EPS of $1.93, which outpaced the Zacks Consensus Estimate by 10.3%. Revenues of $55.26 billion exceeded the Zacks Consensus Estimate by 0.7%.
CAH has an estimated five-year earnings growth rate of 10.7% compared with the industry’s 9.3%. The company’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 9.6%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
ALGN Q4 Earnings Top Estimates, Revenues Miss, Stock Falls
Align Technology, Inc. (ALGN - Free Report) delivered fourth-quarter 2024 adjusted earnings per share (EPS) of $2.44, up 0.8% from the year-ago level. The reported figure topped the Zacks Consensus Estimate by 0.4%.
Find the latest EPS estimates and surprises on Zacks Earnings Calendar.
GAAP EPS for the quarter was $1.39, reflecting a decline of 15.2% from $1.64 in the comparable period of 2023.
Full-year adjusted EPS was $9.33, reflecting an 8.4% increase from the 2023 level. The figure surpassed the Zacks Consensus Estimate by 0.1%.
Following the earnings announcement, ALGN stock plunged 0.8% yesterday.
ALGN’s Q4 Revenues
The top line increased 4% year over year to $995.2 million but missed the Zacks Consensus Estimate by 0.2%. Revenues were favorably impacted by foreign exchange of approximately $0.9 million.
Full-year revenues totaled $4.00 billion, up 3.5% from the 2023 level. The figure was in line with the Zacks Consensus Estimate.
ALGN’s Segments in Detail
The company has two reportable segments — Clear Aligner, and Imaging Systems and CAD/CAM Services (Systems and Services).
Revenues in the Clear Aligner segment rose 1.6% year over year to $794.3 million.
Clear Aligner revenues had a 0.1% unfavorable foreign exchange impact.
Revenues from Imaging Systems & CAD/CAM Services rose 14.9% to $200.9 million in the reported quarter. The segment, too, witnessed an unfavorable currency impact of 0.1% year over year.
Margins
Gross profit in the quarter was $696.9 million, up 4.1% year over year. The gross margin expanded 5 basis points (bps) year over year to 70% despite an increase of 3.9% in the cost of net revenues.
SG&A expenses increased 5.6% to $425 million, while R&D expenses rose 15.5% to $94.9 million.
Operating income totaled $177.1 million, down 4.2% year over year. The operating margin contracted 153 bps to 17.8%.
Financial Details of ALGN
The company exited the fourth quarter with cash and cash equivalents of $1.04 billion, compared with $937.4 million at the end of the fourth quarter of 2023.
The cumulative net cash provided by operating activities at the end of 2024 was $738.2 million compared with $785.8 million at the end of 2023.
Stock Repurchase
Currently, $225 million is available for repurchases under ALGN’s $1.0 billion Stock Repurchase Program, authorized in January 2023.
ALGN's Guidance
Align Technology provided its financial outlook for full-year 2025. It also provided a guidance for the first quarter of 2025.
Align Technology, Inc. Price, Consensus and EPS Surprise
Align Technology, Inc. price-consensus-eps-surprise-chart | Align Technology, Inc. Quote
For the full year, ALGN expects revenue growth to be in the low single digits, which suggests approximately 2% of unfavorable foreign exchange impact at current spot rates. The Zacks Consensus Estimate for 2025 revenues is pegged at $4.19 billion, suggesting 4.8% growth year over year.
The 2025 GAAP operating margin for the full year is anticipated to be approximately 2 basis points above the 2024 level. The 2025 non-GAAP operating margin is expected to be approximately 22.5%.
To support continued expansion, the company expects to invest in the range of $100-$150 million in capital expenditures, primarily related to building construction and improvements and manufacturing capacity.
For the first quarter, ALGN anticipates worldwide revenues to be in the band of $965-$985 million. The Zacks Consensus Estimate is pegged at $1.02 billion.
Our Take
Align Technology exited the fourth quarter on a mixed note. While earnings beat the Zacks Consensus Estimate, revenues lagged the same. Revenues improved on a year-over-year basis, driven by growth in Clear Aligner volumes and Imaging Systems and CAD/CAM Services revenues.
Clear Aligner's volume growth was driven by increased shipments across all regions the company operates in. It experienced continued growth momentum from sales of iTero Lumina scanners and increased Invisalign Clear Aligner volumes in the EMEA region.
Additionally, ALGN’s Imaging Systems & CAD/CAM Services business segment reported strong growth on a year-over-year basis, primarily due to higher ASPs, improved services revenues and increased non-system revenues driven by upgrades in the leasing rental programs.
During the quarter, Align Technology achieved several cumulative milestones, including 271.6 thousand active Invisalign-trained practitioners, 19.5 million Invisalign patients (including over 5.6 million teens and kids) and more than 2 billion clear aligners manufactured worldwide.
Further, a declining operating income and a contraction of the operating margin are matters of concern.
ALGN’s Zacks Rank and Key Picks
Align Technology currently carries a Zacks Rank #4 (Sell).
Some better-ranked stocks from the broader medical space are Quest Diagnostics (DGX - Free Report) , ResMed (RMD - Free Report) and Cardinal Health (CAH - Free Report) .
Quest Diagnostics reported fourth-quarter 2024 adjusted EPS of $2.23, which topped the Zacks Consensus Estimate by 1.8%. Revenues of $2.62 billion beat the Zacks Consensus Estimate by 1.9%.
DGX carries a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
DGX has an earnings yield of 5.9% compared with the industry’s 4.1%. The company beat on earnings in each of the trailing four quarters, the average surprise being 3.8%.
ResMed, carrying a Zacks Rank #2 at present, posted second-quarter fiscal 2025 adjusted EPS of $2.43, which topped the Zacks Consensus Estimate by 5.6%. Revenues of $1.28 billion exceeded the Zacks Consensus Estimate by 1.6%.
RMD has an estimated fiscal 2025 earnings growth rate of 21.9% compared with the industry’s 13.2%. The company’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 6.9%.
Cardinal Health, carrying a Zacks Rank #2 at present, posted second-quarter fiscal 2025 adjusted EPS of $1.93, which outpaced the Zacks Consensus Estimate by 10.3%. Revenues of $55.26 billion exceeded the Zacks Consensus Estimate by 0.7%.
CAH has an estimated five-year earnings growth rate of 10.7% compared with the industry’s 9.3%. The company’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 9.6%.